Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 3 1Phase 1 1

Status

Active not recruiting 3Recruiting 1Completed 1

Sponsor Class

OTHER 3NIH 1INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 5Genitourinary 1

Conditions

Breast Neoplasms 39Ovarian Neoplasms 32Triple Negative Breast Neoplasms 19Prostatic Neoplasms 17Fallopian Tube Neoplasms 16Neoplasm Metastasis 14Pancreatic Neoplasms 9Neoplasms 9Endometrial Neoplasms 9Carcinoma, Non-Small-Cell Lung 7Small Cell Lung Carcinoma 6Parkinson Disease 4, Autosomal Dominant Lewy Body 6Glioma 6Stomach Neoplasms 5Sarcoma 5Lung Neoplasms 5Glioblastoma 5Squamous Cell Carcinoma of Head and Neck 4Metastatic Castration-resistant Prostate Cancer 4Carcinoma, Ovarian Epithelial 4Solid Tumors 3Recurrence 3Osteosarcoma 3Neuroendocrine Tumors 3Lymphoma, Non-Hodgkin 3Cholangiocarcinoma 3Urinary Bladder Neoplasms 2Sarcoma, Ewing 2Rhabdomyosarcoma 2Prostatic Neoplasms, Castration-Resistant 2

Interventions

pembrolizumab 88Carboplatin 77Specimen Handling 76Magnetic Resonance Spectroscopy 63Pemetrexed 59Cisplatin 47durvalumab 44Paclitaxel 38Nivolumab 34atezolizumab 32osimertinib 29Radiotherapy 29Radiosurgery 29Biopsy 26Blood Specimen Collection 25Gemcitabine 24Docetaxel 24Immunoglobulin G 23Disulfides 22Standard of Care 21Drug Therapy 21Etoposide 19Taxes 18Practice Guidelines as Topic 18Radiation 17Educational Status 16130-nm albumin-bound paclitaxel 15X-Rays 14Surveys and Questionnaires 14Bevacizumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Lung Neoplasms × olaparib × 1 year × Clear all
NCT04380636 2026-05-15

MK-7339-012

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
870 enrolled
Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06217757 2026-05-05

Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC

Sichuan University

Phase 1/2 Recruiting
45 enrolled
Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

NCT03923270 2026-04-01

Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Active not recruiting
25 enrolled
Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

NCT04728230 2025-12-18

Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO Trial

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
63 enrolled
Thoracic

Lung Neoplasms

NCT02769962 2025-07-28

Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
45 enrolled 30 charts
GenitourinaryThoracic

Carcinoma, Transitional Cell, Lung Neoplasms, Prostatic Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡